Literature DB >> 15716622

Neostigmine for the treatment of acute hepatic encephalopathy with acute intestinal pseudo-obstruction in a cirrhotic patient.

Chang Hwan Park1, Young Eun Joo, Hyun Soo Kim, Sung Kyu Choi, Jong Sun Rew, Sei Jong Kim.   

Abstract

We treated a 49-yr-old man with neostigmine, who had liver cirrhosis, acute hepatic encephalopathy, and acute intestinal pseudoobstruction. He was admitted in a state of hepatic confusion. On physical examination, the abdomen was distended; and bowel sound was absent. Plain abdomen film revealed multiple air-fluid levels and distention of bowel loops. Initially, we gave him lactulose enemas every 6 hr for one day without improvement in his mental state. Furthermore, he became to a state of coma. Therefore, we gave him 0.5 mg of neostigmine subcutaneously to improve his peristaltic movement, and 2 L of polyethylene glycol electrolyte solution through a nasogastric tube for 4 hr to reduce the production and absorption of gut-derived toxins of nitrogenous compounds. After these treatments, the venous ammonia level decreased to the normal range within 12 hr, and the coma disappeared after 2 days. We suggest that neostigmine may be one of the most effective treatments to initiate peristaltic movement and bowel cleansing in cirrhotic patients with acute hepatic encephalopathy and acute intestinal pseudoobstruction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15716622      PMCID: PMC2808564          DOI: 10.3346/jkms.2005.20.1.150

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  12 in total

Review 1.  Abdominal pressure in the critically ill: measurement and clinical relevance.

Authors:  M L Malbrain
Journal:  Intensive Care Med       Date:  1999-12       Impact factor: 17.440

2.  Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction.

Authors:  G T Trevisani; N H Hyman; J M Church
Journal:  Dis Colon Rectum       Date:  2000-05       Impact factor: 4.585

Review 3.  Pseudo-obstruction in the critically ill.

Authors:  Silvia Delgado-Aros; Michael Camilleri
Journal:  Best Pract Res Clin Gastroenterol       Date:  2003-06       Impact factor: 3.043

4.  Neostigmine infusion: new standard of care for acute colonic pseudo-obstruction?

Authors:  R Amaro; A I Rogers
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

5.  Hepatic Encephalopathy.

Authors:  A T Blei; J Córdoba
Journal:  Am J Gastroenterol       Date:  2001-07       Impact factor: 10.864

6.  Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial.

Authors:  M Y Morgan; K E Hawley
Journal:  Hepatology       Date:  1987 Nov-Dec       Impact factor: 17.425

7.  Neostigmine for the treatment of acute colonic pseudo-obstruction.

Authors:  R J Ponec; M D Saunders; M B Kimmey
Journal:  N Engl J Med       Date:  1999-07-15       Impact factor: 91.245

8.  The importance of bacterial infections as precipating factors of chronic hepatic encephalopathy in cirrhosis.

Authors:  E Strauss; M F da Costa
Journal:  Hepatogastroenterology       Date:  1998 May-Jun

9.  Fatal bacterial peritonitis secondary to nonobstructive colonic dilatation (Ogilvie's syndrome) in cirrhotic ascites.

Authors:  B A Runyon
Journal:  J Clin Gastroenterol       Date:  1986-12       Impact factor: 3.062

10.  Neostigmine and polyethylene glycol electrolyte solution for the therapy of acute hepatic encephalopathy with liver cirrhosis and ascites.

Authors:  Takayoshi Kiba; Kazushi Numata; Satoru Saito
Journal:  Hepatogastroenterology       Date:  2003 May-Jun
View more
  3 in total

1.  The role of the gut microbiota in nonalcoholic fatty liver disease.

Authors:  Ahmed Abu-Shanab; Eamonn M M Quigley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

2.  Hemodiafiltration for hepatic encephalopathy induced by Budd-Chiari syndrome in a patient with end-stage kidney disease.

Authors:  Takuya Wakamatsu; Suguru Yamamoto; Kenya Kamimura; Takeshi Nakatsue; Noriaki Iino; Seitaro Iguchi; Yoshikatsu Kaneko; Shin Goto; Junichiro James Kazama; Ichiei Narita
Journal:  CEN Case Rep       Date:  2015-12-11

3.  Erythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: a randomized double-blind study.

Authors:  Fernando Gomes Romeiro; Fabio da Silva Yamashiro; Madileine Francely Américo; Luciana Aparecida Corá; Giovanni Faria Silva; José Ricardo de Arruda Miranda; Carlos Antonio Caramori
Journal:  BMC Gastroenterol       Date:  2013-01-16       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.